Brought to you by 
Adamas nets $42.7mm via IPO
26 Jan 2018
Executive Summary
Adamas Pharmaceuticals Inc. (working on combination therapies for central nervous system disorders) netted $42.7mm in its initial public offering of 3.08mm common shares (including the overallotment) at $16 each, the low end of its intended $16-18 range.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Adamas nets $42.7mm via IPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice